Cas:26334-33-8 (r,s)-4-isobutyloxazolidine-2,5-dione manufacturer & supplier

We serve Chemical Name:(r,s)-4-isobutyloxazolidine-2,5-dione CAS:26334-33-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(r,s)-4-isobutyloxazolidine-2,5-dione

Chemical Name:(r,s)-4-isobutyloxazolidine-2,5-dione
CAS.NO:26334-33-8
Synonyms:N-CARBOXY-DL-LEUCINE ANHYDRIDE;D-Leucine NCA;4-Isobutyl-1,3-Oxazolidine-2,5-Dione;DL-4-ISOBUTYLOXAZOLIDINE-2,5-DIONE;D-leucine N-carboxyanhydride
Molecular Formula:C7H11NO3
Molecular Weight:157.16700
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.124g/cm3
Index of Refraction:1.45
PSA:55.40000
Exact Mass:157.07400
LogP:0.99630

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like N-CARBOXY-DL-LEUCINE ANHYDRIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-leucine N-carboxyanhydride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-Leucine NCA Use and application,4-Isobutyl-1,3-Oxazolidine-2,5-Dione technical grade,usp/ep/jp grade.


Related News: After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease. Methyl-(O4,O6-benzyliden-2-dithiomethoxycarbonylamino-2-desoxy-β-D-glucopyranosid) manufacturers Not only will we be able to better support our enterprise partners and their teams, we’ll be helping individual members unlock their full potential and achieve peak performance.” β-(o-Toloxy)aethylcarbanilat suppliers The results provided a formulation amenable to two dosage strengths by applying a proportional dosing weight method.” The product is currently in late-stage development with the New Drug Application filing expected in late 2021. 4-[4-(2-carboxy-ethyl)-phenyl]-4-oxo-butyric acid vendor & factory.